Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Symptoms of pancreatic cancer include jaundice, weight loss, and abdominal pain
It is the first dual GIP/GLP-1 receptor co-agonist that activates key receptors involved in insulin secretion and food intake regulation
Ultimately, the right choice comes down to your medical history, current medications, metabolic health, and weight loss goals not just which medication performed better in a study population
#AcuteDecompensation #ACLF #Inflammation #LiverDisease #GENFIT #G1090N *G1090N is an investigational drug candidate.* European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Liver Patients' Association - ELPA Global Liver Institute American Liver Foundation To view or add a comment, sign in Following recent Phase 1 data that provided a solid foundation for advancing G1090N into Phase 2 proof-of-concept studies across the ACLF continuum, explore our latest scientific poster presented at AASLD 2025 to learn more about its active metabolite and earlier body of evidence
US$ 22.93
US$ 25.22
US$ 21.78
US$ 23.18
